SCHEMBL4262134

SCHEMBL4262134

COC(=O)CCc1ccc(OCC(=O)OC)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.58
ADRB1 P08588 1/20 0.58
F2RL1 P55085 1/20 0.53
PTGS2 P35354 2/20 0.53
ALDH1A1 P00352 2/20 0.50
KMT2A Q03164 2/20 0.50
LMNA P02545 2/20 0.50
FFAR1 O14842 1/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PPARD Q03181 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23810493 0.90 ADRB2 (0.56) ADRB2ADRB1F2RL1KMT2ALMNA
SCHEMBL1586881 0.90 FFAR1 (0.63) F2RL1PTGS2LMNAFFAR1L3MBTL1
SCHEMBL9812051 0.90 LMNA (0.53) ADRB2ADRB1F2RL1PTGS2ALDH1A1
SCHEMBL8402471 0.90 ADRB2 (0.56) ADRB2ADRB1F2RL1ALDH1A1KMT2A
SCHEMBL1586600 0.88 ADRB2 (0.54) ADRB2ADRB1F2RL1PTGS2KMT2A
SCHEMBL1586571 0.88 ADRB2 (0.51) ADRB2ADRB1F2RL1PTGS2ALDH1A1
SCHEMBL8481490 0.86 PTGS2 (0.53) F2RL1PTGS2ALDH1A1KMT2ALMNA
SCHEMBL12548774 0.86 HTT (0.60) ADRB2ADRB1F2RL1ALDH1A1KMT2A
SCHEMBL7328232 0.86 CYP4F2 (0.64) F2RL1PTGS2ALDH1A1KMT2ALMNA
SCHEMBL10805292 0.86 PPARD (0.58) PTGS2ALDH1A1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802892-B2 Functionalized phenolic compounds and polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2014-08-12 US disclosed
US-8802892-B2 Functionalized phenolic compounds and polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2014-08-12 US disclosed
US-8802892-B2 Functionalized phenolic compounds and polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2014-08-12 US disclosed
US-20130281652-A1 FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC 2013-10-24 US disclosed
US-20130281652-A1 FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC 2013-10-24 US disclosed
US-20130281652-A1 FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC 2013-10-24 US disclosed
US-8318973-B2 Functionalized sinapic acid and methyl sinapate BEZWADA BIOMEDICAL, LLC (US) 2012-11-27 US disclosed
US-8318973-B2 Functionalized sinapic acid and methyl sinapate BEZWADA BIOMEDICAL, LLC (US) 2012-11-27 US disclosed
US-8318973-B2 Functionalized sinapic acid and methyl sinapate BEZWADA BIOMEDICAL, LLC (US) 2012-11-27 US disclosed
US-20090170927-A1 FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC (US) 2009-07-02 US disclosed
US-20090170927-A1 FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC (US) 2009-07-02 US disclosed
US-20090170927-A1 FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC (US) 2009-07-02 US disclosed
EP-1951260-A2 FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM Bezwada Biomedical LLC (US) 2008-08-06 EP disclosed
WO-2007053794-A2 FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-05-10 WO disclosed
WO-2007053794-A2 FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170927-A1 FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM COMT, AOX1, UGT1A6 ADRB2 503/4885ADRB1 170/4885F2RL1 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.